Safety and Efficacy of ABT-494 (Upadacitinib), an Oral Jak1 Inhibitor, as Induction Therapy in Patients with Crohn's Disease: Results from Celest

この論文をさがす

収録刊行物

被引用文献 (1)*注記

もっと見る

問題の指摘

ページトップへ